Hypoparathyroidism (Adult)

1. Clinical Overview

Executive Summary

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient secretion of parathyroid hormone (PTH) from the parathyroid glands, resulting in hypocalcaemia and hyperphosphataemia. [1] Unlike other classic endocrine deficiency states, hypoparathyroidism represents the only major hormonal insufficiency where direct hormone replacement is not the standard first-line therapy, though recombinant PTH therapies have emerged in recent years. [2]

The condition affects approximately 60,000-80,000 individuals in the United States, with post-surgical injury accounting for 75% of cases. [3] The hallmark biochemical triad consists of low serum calcium, elevated serum phosphate, and inappropriately low or absent PTH levels. Clinical manifestations range from asymptomatic biochemical abnormalities to life-threatening neuromuscular irritability, cardiac arrhythmias, and seizures.

Pathophysiological Significance

The parathyroid glands, typically four rice-grain-sized structures located posterior to the thyroid gland, are the body's principal calcium-sensing organs. Through PTH secretion, they orchestrate a sophisticated calcium homeostatic system involving bone resorption, renal calcium reabsorption, and intestinal calcium absorption via vitamin D activation. [4]

In hypoparathyroidism, this regulatory axis collapses, leading to:

• Skeletal effects: Loss of PTH-mediated bone remodeling
• Renal effects: Decreased calcium reabsorption and phosphate excretion
• Intestinal effects: Impaired vitamin D activation reduces calcium absorption
• Neuromuscular effects: Hypocalcaemia-induced membrane instability

The chronic absence of PTH creates a paradoxical situation where conventional therapy (calcium and active vitamin D supplementation) can achieve target serum calcium levels but at the cost of hypercalciuria and potential renal damage. [5]

Clinical Pearls

The "Hungry Bone" Syndrome: Following parathyroidectomy for hyperparathyroidism, the sudden withdrawal of chronically elevated PTH triggers massive skeletal calcium uptake, resulting in severe acute hypocalcaemia. Bones previously subjected to PTH-driven osteoclastic resorption become avid calcium sinks. This phenomenon, while transient, presents identically to permanent hypoparathyroidism and requires aggressive calcium replacement. The distinction lies in recovery trajectory—hungry bone syndrome typically resolves within 6-12 months as bone remineralization plateaus. [6]

Magnesium: The Master Controller: Magnesium serves dual critical roles in PTH physiology—it is essential for both PTH secretion from chief cells and PTH receptor signaling in target tissues. Severe hypomagnesemia (< 0.4 mmol/L) causes functional hypoparathyroidism with low PTH levels, while moderate depletion can cause PTH resistance. [7] Common culprits include proton pump inhibitors, loop diuretics, alcohol abuse, and malabsorption syndromes. No amount of calcium supplementation will correct hypocalcaemia until magnesium is repleted. This represents a critical diagnostic and therapeutic consideration.

Trousseau's Sign: The Pathognomonic Test: While Chvostek's sign (facial twitching with facial nerve percussion) is positive in 10-30% of normocalcaemic individuals, Trousseau's sign demonstrates superior specificity. [8] Inflate a blood pressure cuff 20 mmHg above systolic pressure and maintain for 3 minutes. A positive response manifests as carpal spasm: flexion at the wrist and metacarpophalangeal joints with extension of the interphalangeal joints and thumb adduction—the classic "main d'accoucheur" or "obstetrician's hand." This posture reflects differential sensitivity of motor neurons to hypocalcaemia-induced membrane depolarization. Positivity rate in hypocalcaemia approaches 94% versus 1-4% in normal individuals.

The QT Interval Paradox: Hypocalcaemia prolongs the QTc interval by extending the plateau phase of the cardiac action potential. [9] However, unlike prolonged QT syndromes from other causes, hypocalcaemic QT prolongation predominantly affects the ST segment with a characteristic "plateau" appearance rather than T-wave abnormalities. The corrected QT interval correlates inversely with serum calcium levels. Acute hypocalcaemia can precipitate torsades de pointes, though less commonly than other QT-prolonging conditions. Chronic hypocalcaemia may paradoxically lead to heart failure through calcium-dependent contractility impairment.

---

2. Epidemiology

Prevalence and Incidence

Hypoparathyroidism represents a rare endocrine disorder with an estimated prevalence of 24-37 per 100,000 population in the United States and Europe. [3,10] Approximately 60,000-80,000 Americans currently live with the condition. The incidence of new permanent cases following thyroid surgery ranges from 0.5-6.6%, with variation depending on surgical indication, extent of resection, and surgeon experience. [11]

Gender distribution shows a female predominance (approximately 3:1) primarily reflecting the higher rate of thyroid surgery in women. [12] Age distribution is bimodal: genetic and autoimmune cases typically present in childhood or young adulthood, while post-surgical hypoparathyroidism peaks in the 4th-6th decades, corresponding to the age distribution of thyroid malignancy and toxic goiter.

Etiological Classification

1. Post-Surgical Hypoparathyroidism (75% of Adult Cases)

The dominant cause of adult hypoparathyroidism results from inadvertent injury, devascularization, or removal of parathyroid glands during anterior neck surgery. [13] Risk factors include:

Thyroid Surgery:

• Total thyroidectomy (higher risk than hemithyroidectomy)
• Revision surgery (3-4× increased risk)
• Thyroid malignancy requiring extensive dissection
• Substernal or retrosternal goiter
• Graves' disease with vascularity and fibrosis

Parathyroid Surgery:

• Exploration for hyperparathyroidism
• Multiple gland resection
• Difficulty identifying glands (especially ectopic locations)

Temporal Classification:

• Transient (< 6 months): Parathyroid gland stunning/ischemia; affects 20-30% post-thyroidectomy
• Permanent (6 months): Irreversible gland loss; affects 1-6% post-thyroidectomy

Intraoperative parathyroid gland autotransplantation (mincing and implanting into sternocleidomastoid or forearm muscle) may prevent permanent deficiency but requires 4-6 weeks for graft function. [14]

2. Autoimmune Hypoparathyroidism (15-20% of Cases)

Isolated Autoimmune Hypoparathyroidism: Antibodies against calcium-sensing receptor (CaSR) or parathyroid-specific proteins result in gland destruction. May occur in isolation or precede other autoimmune endocrinopathies. [15]

Autoimmune Polyglandular Syndrome Type 1 (APS-1): Also known as APECED (Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy), this rare autosomal recessive condition results from mutations in the AIRE gene (21q22.3). [16]

Classic Triad:

• Chronic mucocutaneous candidiasis (typically first manifestation)
• Hypoparathyroidism
• Adrenal insufficiency (Addison's disease)

Diagnosis requires 2 of 3 major criteria. Additional features include hypogonadism, type 1 diabetes, autoimmune thyroid disease, pernicious anemia, alopecia, vitiligo, and dental enamel hypoplasia.

3. Genetic Hypoparathyroidism (5-10% of Cases)

DiGeorge Syndrome (22q11.2 Deletion Syndrome): The most common chromosomal microdeletion syndrome (1 in 4,000 live births) results from haploinsufficiency of TBX1 and other genes. [17] Clinical features include:

• Cardiac defects (conotruncal abnormalities)
• Abnormal facies (hypertelorism, micrognathia, low-set ears)
• Thymic hypoplasia (T-cell immunodeficiency)
• Cleft palate
• Hypocalcemia (parathyroid hypoplasia/aplasia)

While typically diagnosed in infancy, mild cases may present in adulthood with isolated hypocalcaemia.

Other Genetic Causes:

• PTH gene mutations (autosomal recessive/dominant)
• GCM2 mutations (parathyroid-specific transcription factor)
• X-linked recessive hypoparathyroidism (SOX3 mutations)
• HDR syndrome (hypoparathyroidism, deafness, renal dysplasia; GATA3 mutations)
• Kenny-Caffey syndrome (tubular bone stenosis with hypoparathyroidism)

4. Infiltrative and Destructive Causes (5% of Cases)

Hemochromatosis and Iron Overload: Excessive iron deposition in parathyroid glands impairs PTH synthesis and secretion. [18]

Wilson's Disease: Copper accumulation may affect parathyroid function, though less commonly than hepatic and neurological manifestations.

Metastatic Infiltration: Breast, lung, and hematological malignancies may infiltrate and destroy parathyroid tissue.

Radiation Injury: Radioiodine therapy for thyroid disease or external beam radiation for head and neck malignancies.

Granulomatous Disease: Sarcoidosis, tuberculosis, or other infiltrative processes rarely affect parathyroid glands.

5. Functional Hypoparathyroidism

Severe Hypomagnesemia: As discussed in clinical pearls, magnesium depletion (< 0.4 mmol/L) impairs PTH secretion and action, creating a reversible functional hypoparathyroid state. [7]

Critical Illness: Acute severe illness may temporarily suppress PTH secretion through unclear mechanisms.

---

3. Pathophysiology

Normal Calcium Homeostasis

The adult human body contains approximately 1,000-1,200 grams of calcium, with 99% residing in the skeletal hydroxyapatite matrix. The remaining 1% exists in extracellular fluid (ECF) and soft tissues. Serum calcium exists in three forms:

• Ionized (free) calcium: ~50% (1.1-1.3 mmol/L)—the physiologically active fraction
• Protein-bound calcium: ~40% (primarily albumin)
• Complexed calcium: ~10% (citrate, phosphate, sulfate)

Total serum calcium normally ranges 2.2-2.6 mmol/L (8.8-10.4 mg/dL). Because albumin binding affects total calcium, the adjusted calcium calculation corrects for hypoalbuminemia:

Adjusted Ca (mmol/L) = Measured Ca + 0.02 × (40 - Albumin g/L)

Or in mg/dL: Adjusted Ca = Measured Ca + 0.8 × (4.0 - Albumin g/dL)

Alternatively, ionized calcium can be measured directly, providing the most accurate assessment of calcium status.

The PTH-Vitamin D-Calcium Axis

Parathyroid Hormone (PTH): An 84-amino acid polypeptide secreted by parathyroid chief cells in response to declining ionized calcium, sensed via the calcium-sensing receptor (CaSR). [4] PTH has a half-life of 2-4 minutes and exerts three primary actions:

1. Bone Effects (Rapid and Delayed):

   • Rapid (minutes-hours): Osteocyte-mediated calcium release from bone fluid
   • Delayed (hours-days): Osteoclastic bone resorption via RANKL upregulation

2. Renal Effects:

   • Calcium reabsorption: Enhanced in distal convoluted tubule via TRPV5 channels
   • Phosphate excretion: Inhibits proximal tubule phosphate reabsorption via NPT2a downregulation
   • 1α-hydroxylase activation: Converts 25(OH)D to active 1,25(OH)₂D (calcitriol)

3. Intestinal Effects (Indirect):

   • Via 1,25(OH)₂D production, enhances intestinal calcium absorption through vitamin D receptor (VDR)-mediated transcription of calcium-binding proteins (calbindins)

Vitamin D Metabolism: Cholecalciferol (vitamin D₃) from skin synthesis or dietary sources undergoes hepatic 25-hydroxylation to 25(OH)D (calcidiol), the storage form measured to assess vitamin D status. The critical activation step occurs in renal proximal tubule cells where PTH-stimulated 1α-hydroxylase converts 25(OH)D to 1,25(OH)₂D (calcitriol), the active hormone. [19]

Pathophysiology of Hypoparathyroidism

In hypoparathyroidism, PTH deficiency or absence disrupts this integrated system:

1. Skeletal Consequences

Loss of Bone Remodeling: Absent PTH eliminates both rapid osteocytic calcium release and delayed osteoclastic resorption. Bone histomorphometry reveals reduced bone turnover with increased bone density (high areal bone mineral density on DXA) but paradoxically abnormal bone microarchitecture and potential fragility. [20] This represents "frozen bone"—high quantity but impaired quality.

2. Renal Dysfunction

Impaired Calcium Reabsorption: Loss of PTH-mediated distal tubule calcium reabsorption leads to inappropriate urinary calcium loss (hypercalciuria) despite hypocalcaemia. This creates a fundamental treatment challenge: raising serum calcium through supplementation increases the filtered calcium load, exacerbating hypercalciuria and risking nephrocalcinosis and nephrolithiasis. [5]

Reduced Phosphate Excretion: PTH normally promotes renal phosphate excretion. Its absence causes phosphate retention and hyperphosphataemia, contributing to calcium-phosphate product elevation and ectopic soft tissue calcification risk.

Impaired Vitamin D Activation: Without PTH stimulation of renal 1α-hydroxylase, 25(OH)D cannot be efficiently converted to active 1,25(OH)₂D. Consequently, intestinal calcium absorption falls dramatically. This explains why cholecalciferol (plain vitamin D) supplementation proves ineffective in hypoparathyroidism—patients require pre-activated vitamin D analogs (alfacalcidol or calcitriol) that bypass the deficient activation step. [21]

3. Neuromuscular Effects

Membrane Hyperexcitability: Ionized calcium stabilizes neuronal and muscle cell membranes by binding to negative charges on membrane proteins and phospholipids, raising the threshold potential for depolarization. Hypocalcaemia reduces this stabilizing effect, bringing the resting membrane potential closer to threshold, causing spontaneous depolarization and neuromuscular irritability. [22]

This manifests as:

• Paresthesias: Perioral and acral numbness/tingling
• Tetany: Carpopedal spasm, laryngospasm
• Seizures: Generalized tonic-clonic from cortical hyperexcitability
• Movement disorders: Basal ganglia calcification (see below)

4. Cardiac Effects

QT Prolongation: Hypocalcaemia prolongs the plateau phase (phase 2) of the cardiac action potential by reducing calcium-dependent inactivation of L-type calcium channels. [9] This manifests as QTc prolongation, predominantly affecting the ST segment. While torsades de pointes can occur, it's less common than with other causes of prolonged QT.

Contractility Impairment: Chronic severe hypocalcaemia impairs excitation-contraction coupling, potentially leading to dilated cardiomyopathy and heart failure.

5. Ectopic Calcification

Basal Ganglia Calcification (Fahr's Syndrome): The combination of hypocalcaemia and hyperphosphataemia paradoxically promotes calcium-phosphate deposition in the basal ganglia, dentate nuclei, and other brain regions. [23] The mechanism remains incompletely understood but likely involves local blood-brain barrier breakdown and altered brain tissue pH. Clinical sequelae include:

• Extrapyramidal movement disorders (parkinsonism, dystonia, chorea)
• Cognitive impairment
• Psychiatric manifestations (psychosis, mood disorders)
• Seizures

Soft Tissue and Vascular Calcification: Elevated calcium-phosphate product (4.4 mmol²/L²) promotes metastatic calcification in blood vessels, heart valves, kidneys, and soft tissues.

The Biochemical Signature

The hallmark biochemistry of hypoparathyroidism includes:

---

4. Differential Diagnosis of Hypocalcaemia

Hypocalcaemia represents the final common pathway of multiple pathologies. Accurate differential diagnosis requires integrating clinical context with biochemical patterns.

Biochemical Differentiation Table

Key Diagnostic Features

1. PTH Level: The Critical Discriminator

• Low or Inappropriately Normal PTH = Primary hypoparathyroid state

  • True hypoparathyroidism
  • Hypomagnesemia-induced
  • Hungry bone syndrome (early)

• Elevated PTH = Appropriate secondary response

  • Vitamin D deficiency
  • Chronic kidney disease
  • Pseudohypoparathyroidism
  • Vitamin D resistance syndromes

2. Phosphate: The Phosphaturic Effect

PTH is a phosphaturic hormone. Its absence causes hyperphosphataemia. Conversely, vitamin D deficiency (high PTH) causes hypophosphataemia through phosphate wasting.

3. Clinical Context Clues

• Recent neck surgery → Post-surgical hypoparathyroidism
• Chronic kidney disease → Renal secondary hyperparathyroidism
• Malnutrition, lack of sun exposure → Vitamin D deficiency
• Phenotypic abnormalities (short 4th/5th metacarpals, round face) → Pseudohypoparathyroidism
• PPI or diuretic use, alcoholism → Hypomagnesemia
• Recent chemotherapy for hematological malignancy → Tumor lysis syndrome

Pseudohypoparathyroidism: The Great Mimic

Pseudohypoparathyroidism (PHP) represents end-organ resistance to PTH due to mutations in GNAS1 (encoding the Gsα protein coupled to PTH receptor signaling). [24] Biochemically, it mimics hypoparathyroidism (low calcium, high phosphate) but PTH is appropriately elevated in response to hypocalcaemia.

Type 1a (Albright's Hereditary Osteodystrophy):

• Short stature
• Round face
• Brachydactyly (short 4th and 5th metacarpals/metatarsals)
• Subcutaneous ossifications
• Cognitive impairment
• Resistance to multiple hormones (PTH, TSH, LH/FSH)

Type 1 b:

• PTH resistance only
• No somatic features

Type 2:

• Rare; defect distal to cAMP generation

---

5. Clinical Presentation

The clinical spectrum of hypoparathyroidism ranges from asymptomatic biochemical abnormalities detected incidentally to life-threatening acute hypocalcaemic crisis. Presentation varies with:

• Rapidity of onset: Acute drop more symptomatic than chronic adaptation
• Severity: Symptoms typically emerge at ionized Ca < 0.9 mmol/L
• Duration: Chronic hypocalcaemia allows partial neurological adaptation

Acute Presentation: The Hypocalcaemic Crisis

Neuromuscular Irritability:

The hallmark of acute hypocalcaemia results from lowered threshold for neuronal and muscle membrane depolarization:

Paresthesias:

• Perioral numbness and tingling (often earliest symptom)
• Acral paresthesias (fingertips, toes)
• May progress in ascending pattern

Tetany:

• Carpopedal spasm: Characteristic "main d'accoucheur" posture
  • Wrist flexion
  • MCP joint flexion
  • Interphalangeal joint extension
  • Thumb adduction across palm
• Laryngospasm: Life-threatening airway obstruction with stridor
• Generalized muscle cramps: Painful sustained contractions
• Bronchospasm: Wheezing and dyspnea

Examination Signs:

Trousseau's Sign (94% Sensitive): Inflate blood pressure cuff 20 mmHg above systolic pressure for 3 minutes. Positive if carpopedal spasm develops. [8]

Chvostek's Sign (Less Specific): Tap facial nerve anterior to ear. Positive if ipsilateral facial muscle twitching occurs. Found in 10-30% of normocalcaemic individuals, limiting specificity.

Neurological Manifestations:

Seizures:

• Generalized tonic-clonic (most common)
• Focal seizures possible
• May be refractory to anticonvulsants until calcium corrected
• EEG may show generalized spike-wave activity

Altered Mental Status:

• Confusion, irritability, anxiety
• Frank psychosis in severe cases
• Depression and mood lability

Raised Intracranial Pressure: Papilledema may occur, particularly in children; mechanism unclear

Cardiovascular Manifestations:

ECG Changes:

• QTc prolongation: Classic finding; correlates inversely with calcium level [9]
• ST segment prolongation: Predominant abnormality (vs. T-wave changes in other long QT)
• T-wave flattening or inversion
• Arrhythmias:
  • Torsades de pointes (rare but life-threatening)
  • Ventricular tachycardia
  • Heart block

Heart Failure: Acute severe hypocalcaemia can precipitate:

• Dilated cardiomyopathy
• Reduced contractility (calcium-dependent excitation-contraction coupling)
• Pulmonary edema

Respiratory:

• Laryngospasm (life-threatening)
• Bronchospasm mimicking asthma
• Respiratory failure in severe cases

Chronic Presentation

Patients with long-standing mild hypocalcaemia may adapt, experiencing subtle symptoms often attributed to other causes:

Constitutional:

• Fatigue (almost universal complaint in patient surveys)
• "Brain fog" and cognitive slowing
• Reduced quality of life scores [25]

Neuropsychiatric:

• Depression and anxiety
• Cognitive impairment
• Personality changes
• Extrapyramidal symptoms (if basal ganglia calcification present)

Dermatological:

• Dry, coarse skin
• Brittle nails
• Coarse, sparse hair
• Eczematous dermatitis
• Candidiasis (particularly in APS-1)

Dental (if Childhood Onset):

• Enamel hypoplasia
• Increased dental caries
• Delayed tooth eruption

Ophthalmological:

• Cataracts: Posterior subcapsular (most common)
  • Occur in 30-50% of chronic hypoparathyroidism [26]
  • "Mechanism: Altered lens calcium-sodium exchange"
  • May be irreversible even with calcium correction

Musculoskeletal:

• Increased bone mineral density on DXA (paradoxically)
• Abnormal bone microarchitecture
• Possible increased fracture risk despite high BMD [20]

Syndromic Features

Autoimmune Polyglandular Syndrome Type 1:

• Chronic mucocutaneous candidiasis (typically first, in childhood)
• Adrenal insufficiency (Addison's disease)
• Hypogonadism
• Hypothyroidism
• Type 1 diabetes
• Pernicious anemia
• Alopecia, vitiligo
• Malabsorption

DiGeorge Syndrome:

• Cardiac defects (conotruncal abnormalities)
• Characteristic facies (hypertelorism, micrognathia, low-set ears)
• Recurrent infections (T-cell immunodeficiency)
• Cleft palate
• Developmental delay

SPASMODIC Mnemonic for Hypocalcaemia

A useful clinical aide-memoire for acute hypocalcaemic symptoms:

• Spasms (Carpopedal, laryngeal)
• Perioral paresthesias
• Anxiety, agitation, altered mental status
• Seizures
• Muscle tone increase (tetany)
• Orientation impairment
• Dermatitis
• Irritability
• Chvostek's sign

---

6. Investigations

Initial Biochemical Assessment

Serum Calcium:

• Total calcium may be misleading in hypoalbuminemia or acid-base disturbances
• Adjusted calcium calculation (see Pathophysiology section)
• Ionized calcium: Gold standard; most accurate in critical care settings
• Hypocalcaemia defined as adjusted Ca < 2.2 mmol/L or ionized Ca < 1.1 mmol/L

Serum Phosphate:

• Typically elevated (1.4 mmol/L) in hypoparathyroidism
• Hyperphosphataemia helps distinguish from vitamin D deficiency (phosphate usually low)

Parathyroid Hormone (PTH):

• Intact PTH assay measures full-length 1-84 amino acid molecule
• In hypoparathyroidism: inappropriately low or undetectable
• "Inappropriately normal" = PTH in normal range despite hypocalcaemia (should be elevated)
• Typical values: < 1.0 pmol/L (normal range 1.5-7.0 pmol/L)

Magnesium:

• Mandatory in every hypocalcaemic work-up
• Severe deficiency (< 0.4 mmol/L) causes functional hypoparathyroidism [7]
• Moderate deficiency impairs PTH action
• Must be corrected before calcium replacement will be effective

25-Hydroxyvitamin D:

• Assess vitamin D stores
• Exclude coexisting vitamin D deficiency (common)
• Target 75 nmol/L for optimal PTH suppression (though less relevant in hypoparathyroidism)

1,25-Dihydroxyvitamin D (Calcitriol):

• Active vitamin D metabolite
• Typically low in hypoparathyroidism due to loss of PTH-driven renal 1α-hydroxylase
• Useful in confirming diagnosis but not routinely required

Renal Function:

• Creatinine and eGFR
• Exclude chronic kidney disease as cause of secondary hyperparathyroidism
• Establish baseline before treatment (risk of nephrocalcinosis)

Albumin:

• Required for adjusted calcium calculation
• Low albumin common in hospitalized patients

Alkaline Phosphatase:

• Typically normal in hypoparathyroidism (low bone turnover)
• Elevated in vitamin D deficiency, CKD, Paget's disease

24-Hour Urine Studies

24-Hour Urinary Calcium:

• Paradoxically elevated in hypoparathyroidism despite hypocalcaemia
• Reflects loss of PTH-mediated tubular calcium reabsorption
• Normal: < 7.5 mmol/24h (men), < 6.25 mmol/24h (women)
• Useful for:
  • Confirming diagnosis
  • "Monitoring treatment (goal: keep < 7.5 mmol/24h to minimize nephrocalcinosis risk)"
  • Titrating therapy to balance serum calcium vs. urinary calcium

24-Hour Urinary Phosphate:

• Low excretion reflects renal phosphate retention

Calcium-Creatinine Ratio (Spot Urine):

• Alternative if 24-hour collection not feasible
• Less accurate but provides estimate of hypercalciuria risk

Electrocardiography

Routine 12-Lead ECG: Essential in all hypocalcaemic patients to assess:

• QTc interval: Calculate using Bazett's formula: QTc = QT / √RR
  • Prolonged if 440 ms (men) or 460 ms (women)
  • Inversely correlates with serum calcium
  • Predominantly affects ST segment (plateau prolongation)
• T-wave changes: Flattening, inversion
• Arrhythmias: Ventricular ectopy, torsades de pointes (rare)
• Heart block: Rare but reported

Serial ECGs during acute treatment guide correction rate and monitor for overcorrection complications.

Radiological Investigations

Renal Tract Imaging:

Ultrasound Kidneys:

• Assess for nephrocalcinosis (medullary hyperechogenicity)
• Detect renal stones
• Baseline before treatment initiation
• Serial monitoring (annually or biannually)

CT Abdomen/Pelvis (Non-Contrast):

• More sensitive than ultrasound for nephrocalcinosis and stones
• Reserved for symptomatic patients or unclear ultrasound

Brain Imaging:

CT Brain (Non-Contrast):

• Identify basal ganglia calcification (Fahr's syndrome)
• Present in up to 50% of chronic hypoparathyroidism [23]
• Appears as symmetric dense calcification in:
  • Basal ganglia (globus pallidus, caudate, putamen)
  • Dentate nuclei of cerebellum
  • Subcortical white matter
• Correlates poorly with symptom severity

MRI Brain:

• If neurological symptoms present
• May show T1 hyperintensity in calcified regions
• Assess for other causes of movement disorders or seizures

Ophthalmological Examination:

Slit-Lamp Examination:

• Screen for cataracts (posterior subcapsular)
• Recommended at diagnosis and periodically during follow-up
• Early detection allows timely intervention

Genetic and Specialized Testing

Indicated in Specific Scenarios:

22q11.2 Deletion Testing (DiGeorge):

• Hypoparathyroidism with cardiac defects, recurrent infections, or developmental delay
• FISH (fluorescence in situ hybridization) or chromosomal microarray

AIRE Gene Sequencing (APS-1):

• Hypoparathyroidism with chronic candidiasis, adrenal insufficiency, or other autoimmune features
• Autosomal recessive inheritance pattern

PTH Gene Sequencing:

• Familial isolated hypoparathyroidism
• Genetic counseling considerations

GCM2, GATA3, CASR Sequencing:

• Indicated based on phenotype and family history

Parathyroid Autoantibodies:

• Research setting; limited clinical availability
• CaSR antibodies, parathyroid-specific antibodies

Bone Density Assessment

Dual-Energy X-Ray Absorptiometry (DXA):

• Paradoxically increased areal BMD in hypoparathyroidism
• Reflects reduced bone turnover ("frozen bone")
• Does NOT indicate superior bone quality
• Fracture risk assessment requires trabecular bone score (TBS) or other microarchitecture measures
• Baseline scan recommended; periodic monitoring debated [20]

---

7. Management

The management of hypoparathyroidism aims to alleviate symptoms, maintain serum calcium in the low-normal range, and minimize long-term complications, particularly hypercalciuria-induced renal damage. Unlike most endocrine deficiencies, direct hormone replacement (recombinant PTH) is not first-line therapy due to cost, route of administration, and regulatory considerations.

Management Principles

1. Target serum calcium in the LOW-NORMAL range (2.0-2.2 mmol/L)
2. Minimize urinary calcium excretion to reduce nephrocalcinosis risk
3. Maintain calcium-phosphate product < 4.4 mmol²/L²
4. Correct magnesium deficiency before or concurrently with calcium
5. Use active vitamin D analogs (not cholecalciferol)
6. Regular monitoring to detect complications early

Acute Hypocalcaemia Management

Acute symptomatic hypocalcaemia (tetany, seizures, laryngospasm, arrhythmia) constitutes a medical emergency requiring immediate intervention.

Step 1: Immediate Stabilization

Intravenous Calcium Gluconate:

• Dose: 10-20 ml of 10% calcium gluconate (90-180 mg elemental calcium) diluted in 50-100 ml 0.9% saline
• Administration: IV over 10-20 minutes
• Effect: Raises serum calcium by ~0.5 mmol/L transiently
• Monitoring: Continuous ECG monitoring essential (bradycardia risk if given too rapidly)
• Extravasation risk: Tissue necrosis if IV infiltrates; use large peripheral or central vein

Alternative: Calcium Chloride:

• Contains 3× more elemental calcium than gluconate per volume
• More irritating to veins
• Preferred in cardiac arrest situations
• Dose: 5-10 ml of 10% calcium chloride

Repeat Boluses:

• May require repeated doses every 10-15 minutes
• Assess clinical response (resolution of paresthesias, tetany)
• Recheck ionized calcium 15-30 minutes after each dose

Step 2: Continuous Infusion

For persistent hypocalcaemia or recurrent symptoms:

Calcium Gluconate Infusion:

• Add 100 ml of 10% calcium gluconate (900 mg elemental Ca) to 900 ml 0.9% saline or 5% dextrose
• Infusion rate: 0.5-2 mg/kg/hour elemental calcium (typically 50-100 ml/hour)
• Continue for 24-48 hours while establishing oral therapy
• Monitor ionized calcium every 4-6 hours
• Adjust rate to maintain ionized Ca 1.0 mmol/L

Step 3: Concurrent Magnesium Replacement

Assess and Correct Hypomagnesemia:

• Check magnesium level immediately
• If Mg < 0.4 mmol/L: IV magnesium sulfate
  • 2 g (8 mmol) IV over 10-15 minutes for severe deficiency
  • "Followed by infusion: 1-2 g/hour for 6-24 hours"
• Target Mg 0.7 mmol/L
• Calcium replacement will be ineffective without magnesium correction [7]

Step 4: Transition to Oral Therapy

Once acute crisis resolves and patient can tolerate oral intake:

Oral Calcium:

• Calcium carbonate: 40% elemental calcium; requires gastric acid for absorption
  • "Typical dose: 1-2 g elemental calcium daily in divided doses"
  • "Examples: Caltrate 600 mg (600 mg elemental Ca per tablet)"
• Calcium citrate: 21% elemental calcium; absorbed independent of gastric pH
  • Better choice for patients on PPIs or with achlorhydria
  • "Typical dose: 1-3 g elemental calcium daily"
• Divide doses: Calcium absorption limited to ~500 mg per dose; give TID or QID

Active Vitamin D Analogs:

Alfacalcidol (1α-hydroxyvitamin D):

• Requires hepatic 25-hydroxylation to become active
• Starting dose: 0.5-1.0 mcg daily
• Titrate every 2-4 weeks based on calcium levels
• Typical maintenance: 0.5-3.0 mcg daily
• Half-life: 3-5 days (allows gradual titration)

Calcitriol (1,25-dihydroxyvitamin D):

• Active form; no metabolism required
• Starting dose: 0.25-0.5 mcg twice daily
• Titrate every 1-2 weeks
• Typical maintenance: 0.5-2.0 mcg daily in divided doses
• Half-life: 4-6 hours (requires multiple daily dosing)
• Faster onset/offset than alfacalcidol

Why NOT Cholecalciferol (Vitamin D3)? Standard vitamin D requires PTH-dependent renal 1α-hydroxylase activation. In hypoparathyroidism, this enzyme is inactive, rendering cholecalciferol ineffective at physiological doses. However, supraphysiological doses (50,000-100,000 IU weekly) can bypass this through mass action, but this is not standard practice. [21]

Chronic Management

Long-term management balances maintaining adequate serum calcium to prevent symptoms while avoiding excessive calcium or vitamin D that would exacerbate hypercalciuria.

Maintenance Therapy

Calcium Supplementation:

• Typical requirement: 1-3 g elemental calcium daily
• Divide into 3-4 doses with meals
• Adjust based on serum calcium and 24-hour urinary calcium

Active Vitamin D:

• Alfacalcidol: 0.5-3.0 mcg daily (preferred for once-daily dosing)
• Calcitriol: 0.5-2.0 mcg daily in divided doses
• Individual variability is substantial; titrate to response

Magnesium Supplementation:

• If ongoing magnesium losses (PPIs, diuretics)
• Magnesium oxide 200-400 mg daily
• Monitor levels periodically

Thiazide Diuretics (For Hypercalciuria)

In patients with persistent hypercalciuria despite optimization:

Hydrochlorothiazide:

• Dose: 12.5-25 mg daily
• Mechanism: Enhances renal tubular calcium reabsorption
• Can reduce urinary calcium by 30-40%
• Allows reduction in calcium/vitamin D doses
• Monitor for hypokalemia, hyponatremia
• Beneficial for patients at high nephrocalcinosis risk [27]

Contraindications:

• Concurrent hypokalemia
• Severe hyponatremia
• Gout

Recombinant PTH Therapy

Teriparatide [PTH(1-34)]:

• Approved for osteoporosis; NOT approved for hypoparathyroidism
• Anabolic bone effects
• Limited study in hypoparathyroidism

Recombinant Human PTH(1-84):

• Brand: Natpar (US), Natpar (EU - withdrawn 2019)
• Indication: Hypoparathyroidism inadequately controlled on calcium and active vitamin D
• Dose: Initial 50 mcg SC daily; titrate to 25-100 mcg
• Administration: Daily subcutaneous injection
• Benefits demonstrated in clinical trials: [2,28]
  • Reduced calcium and active vitamin D requirements
  • Improved serum calcium stability
  • Reduced urinary calcium excretion
  • Improved quality of life scores
• Limitations:
  • Cost (>$50,000/year in US)
  • Daily injections
  • Availability limited (US only currently)
  • "Black box warning: Osteosarcoma risk (based on rat studies)"
  • Not first-line therapy

Selection Criteria for PTH(1-84):

• Refractory hypocalcaemia despite high-dose calcium/vitamin D
• Persistent severe hypercalciuria with nephrocalcinosis
• Unacceptable quality of life on conventional therapy
• Contraindications to high-dose calcium (e.g., severe cardiovascular calcification)

Monitoring and Treatment Targets

Biochemical Targets

Monitoring Schedule

Acute Phase (First 3 Months):

• Serum calcium, phosphate, magnesium: Every 1-2 weeks initially, then monthly
• Adjust therapy based on results
• 24-hour urinary calcium: Once stable on therapy

Stable Maintenance:

• Serum calcium, phosphate, magnesium: Every 3-6 months
• 24-hour urinary calcium: Every 6-12 months
• Renal function (creatinine, eGFR): Every 6-12 months
• Renal ultrasound: Every 1-2 years (or if symptoms suggest stones)

Annual Assessments:

• Ophthalmology review (cataract screening)
• Consider DXA scan (though interpretation difficult)
• Quality of life questionnaires

Special Situations

Pregnancy

Pregnancy presents unique challenges in hypoparathyroidism management:

Physiological Changes:

• Increased calcium requirements for fetal skeletal development
• Increased calcitriol production by placenta
• Altered calcium kinetics

Management Adjustments:

• Calcium requirements often increase in 2nd-3rd trimester
• Active vitamin D doses may need reduction (placental production)
• Target ionized calcium in low-normal range
• Monthly calcium monitoring
• Fetal ultrasound monitoring for skeletal development
• Coordinate with maternal-fetal medicine specialists

Breastfeeding:

• Calcium demands continue postpartum
• Calcitriol excreted in breast milk (minimal)
• Continue calcium and vitamin D supplementation
• Monitor infant calcium if high-dose therapy

Surgery and Perioperative Management

For hypoparathyroid patients requiring surgery:

Preoperative:

• Optimize calcium to low-normal range
• Document baseline ionized calcium
• Continue oral therapy until day of surgery
• Alert anesthesia team

Intraoperative:

• Check ionized calcium intraoperatively if prolonged procedure
• Have IV calcium available

Postoperative:

• Early calcium monitoring (every 4-6 hours initially)
• IV calcium infusion if NPO prolonged
• Resume oral therapy as soon as tolerated
• Stress, illness, and NPO status can destabilize calcium

---

8. Complications

Renal Complications

Nephrocalcinosis: The most concerning long-term complication of conventional hypoparathyroidism treatment results from the fundamental paradox: raising serum calcium increases filtered calcium load, but without PTH, the kidney cannot reabsorb it, leading to hypercalciuria. [5]

• Prevalence: Affects 30-40% of conventionally treated patients
• Mechanism: Calcium-phosphate precipitation in renal medullary interstitium
• Detection: Renal ultrasound (medullary hyperechogenicity) or CT
• Consequences:
  • Progressive renal dysfunction
  • Chronic kidney disease
  • Increased infection risk

Prevention Strategies:

• Target low-normal serum calcium (avoid overcorrection)
• Monitor 24-hour urinary calcium
• Thiazide diuretics if hypercalciuria persistent
• Adequate hydration (2-3 L daily)
• Limit sodium intake (< 2-3 g/day; sodium increases calciuria)

Nephrolithiasis:

• Calcium-containing renal stones
• Clinical presentation: Renal colic, hematuria, UTI
• Management: Standard stone management plus optimization of underlying therapy

Chronic Kidney Disease:

• Progressive nephron loss from nephrocalcinosis
• May eventually require renal replacement therapy
• Creates additional complexity (CKD worsens phosphate retention)

Neurological Complications

Basal Ganglia Calcification (Fahr's Syndrome): Affects up to 50% of patients with chronic hypoparathyroidism. [23] Bilateral symmetric calcification of:

• Basal ganglia (globus pallidus, putamen, caudate)
• Dentate nuclei (cerebellum)
• Subcortical white matter
• Cerebral cortex (rare)

Clinical Manifestations:

• Often asymptomatic (incidental imaging finding)
• Extrapyramidal movement disorders:
  • Parkinsonism (bradykinesia, rigidity, tremor)
  • Dystonia
  • Chorea
  • Athetosis
• Cognitive impairment
• Psychiatric symptoms (psychosis, depression, mood lability)
• Seizures
• Cerebellar signs (ataxia)

Pathophysiology: Mechanism incompletely understood. Hyperphosphataemia and hypocalcaemia paradoxically promote calcium-phosphate deposition. Blood-brain barrier dysfunction and altered local pH may contribute.

Management:

• Correction of calcium and phosphate may halt progression
• Established calcification is irreversible
• Symptomatic treatment of movement disorders (dopaminergic agents, though response variable)

Seizures:

• Occur in acute hypocalcaemia
• Generalized tonic-clonic most common
• May be refractory to anticonvulsants until calcium corrected
• Antiepileptic drugs not required long-term if calcium controlled

Cognitive and Psychiatric Effects: Even with biochemical control, many patients report:

• "Brain fog" and reduced concentration
• Memory impairment
• Fatigue
• Depression and anxiety
• Reduced quality of life [25]

Mechanisms unclear—may reflect:

• Subclinical calcium fluctuations
• Absence of PTH's direct CNS effects
• Basal ganglia calcification
• Chronic illness burden

Ophthalmological Complications

Cataracts:

• Prevalence: 30-50% in chronic hypoparathyroidism [26]
• Type: Posterior subcapsular most common
• Mechanism: Altered lens calcium-sodium exchange; osmotic stress
• Progression: Often irreversible even with calcium normalization
• Management: Cataract extraction when visually significant
• Prevention: Early diagnosis and treatment may reduce risk

Papilledema: Rare; mechanism uncertain. Consider in patients with headache, visual symptoms.

Cardiovascular Complications

Cardiomyopathy:

• Chronic hypocalcaemia impairs myocardial contractility
• Dilated cardiomyopathy reported
• Heart failure may develop
• Reversible with calcium correction if detected early

Arrhythmias:

• QTc prolongation and torsades de pointes (acute)
• Increased arrhythmia risk with concurrent QT-prolonging medications
• Sudden cardiac death (rare)

Vascular and Valvular Calcification:

• Elevated calcium-phosphate product promotes vascular calcification
• Coronary artery calcification
• Heart valve calcification (stenosis/regurgitation)
• Increased cardiovascular mortality

Skeletal Complications

Bone Quality Paradox: Despite high areal bone mineral density on DXA (low turnover state), chronic hypoparathyroidism may impair bone quality:

• Abnormal bone microarchitecture [20]
• Reduced bone turnover ("frozen bone")
• Possible increased fracture risk (data conflicting)
• Heterotopic ossification (soft tissue calcification)

Dental Complications

If Onset in Childhood:

• Enamel hypoplasia
• Increased dental caries
• Delayed tooth eruption
• Root abnormalities

Metabolic and Other Complications

Soft Tissue Calcification:

• Subcutaneous calcifications
• Visceral calcification
• Calcium-phosphate product 4.4 mmol²/L² increases risk

Paresthesias and Neuromuscular Symptoms:

• May persist despite biochemical control
• Neuropathic pain syndromes

Infections (APS-1 Specific):

• Chronic mucocutaneous candidiasis
• Immune dysregulation

---

9. Prognosis and Quality of Life

Life Expectancy

With appropriate management, life expectancy in hypoparathyroidism approaches that of the general population, though some studies suggest modest mortality increase related to:

• Cardiovascular complications
• Renal complications
• Neuropsychiatric consequences (potentially increased suicide risk) [29]

Post-surgical hypoparathyroidism carries better prognosis than genetic or autoimmune forms, likely reflecting isolated endocrine defect versus syndromic involvement.

Recovery from Post-Surgical Hypoparathyroidism

Transient vs. Permanent:

• Transient (< 6 months): Occurs in 20-30% post-thyroidectomy
  • Results from parathyroid gland stunning, edema, or ischemia
  • Most recover within 6-12 weeks
  • Some require 6+ months
• Permanent (6 months): Affects 1-6% post-thyroidectomy
  • Gland devascularization or inadvertent removal
  • 70% of post-surgical cases that persist 6 months will be permanent [30]

Predictors of Permanence:

• All four glands not visualized intraoperatively
• Need for autotransplantation
• Revision surgery
• Extensive neck dissection
• Very low post-operative PTH (< 1.0 pmol/L)

Quality of Life

Despite biochemical control, patient-reported quality of life in hypoparathyroidism is often significantly impaired compared to healthy controls and even to patients with other chronic endocrine disorders. [25]

Common Patient Complaints:

• Physical fatigue (70-80% of patients)
• Cognitive dysfunction ("brain fog," poor concentration, memory impairment)
• Muscle pain and weakness
• Paresthesias (even with normal calcium)
• Depression and anxiety
• Sleep disturbances
• Reduced work productivity

Potential Contributing Factors:

• Inability to achieve true physiological calcium homeostasis
• Absence of PTH's direct effects on tissues (CNS, bone, muscle)
• Calcium fluctuations despite "normal" levels on monitoring
• Treatment burden (multiple daily medications, frequent monitoring)
• Chronic illness stress
• Subclinical deficiencies (magnesium, vitamin D)
• Comorbidities (basal ganglia calcification, cataracts)

Quality of Life Improvements with rhPTH: Clinical trials of recombinant PTH(1-84) demonstrate improvements in:

• Physical functioning scores
• Mental health scores
• Energy/vitality
• Symptom burden [28]

These benefits suggest PTH has effects beyond simple calcium regulation, though cost and availability limit widespread use.

Long-Term Monitoring Burden

Patients require lifelong:

• Regular biochemical monitoring (every 3-6 months)
• Renal imaging surveillance (annually or biannually)
• Ophthalmology screening (annually)
• Medication adherence (multiple daily doses)
• Prompt response to intercurrent illness
• Awareness of emergency symptoms

This creates significant treatment burden and healthcare utilization.

Special Population Outcomes

Pregnancy: Successful pregnancy outcomes are achievable with meticulous management and multidisciplinary coordination. Maternal hypocalcaemia can lead to fetal hyperparathyroidism and neonatal complications.

Pediatric Onset: Children with hypoparathyroidism face additional challenges:

• Dental abnormalities
• Potential neurodevelopmental effects
• Growth concerns
• Lifetime treatment burden
• Psychosocial impact

Elderly:

• Increased fall and fracture risk (despite high BMD)
• Polypharmacy interactions
• Reduced renal function complicating management
• Cognitive symptoms may be attributed to aging

---

10. Evidence and Guidelines

Key Clinical Guidelines

European Society of Endocrinology (ESE) 2015: The most comprehensive guideline for chronic hypoparathyroidism management. [1]

Key Recommendations:

• Target serum calcium in low-normal range (2.0-2.2 mmol/L)
• Monitor 24-hour urinary calcium; maintain < 7.5 mmol/day
• Use active vitamin D analogs (alfacalcidol or calcitriol), not cholecalciferol
• Add thiazide diuretics for persistent hypercalciuria
• Screen for nephrocalcinosis and cataracts
• Consider rhPTH(1-84) for refractory cases
• Multidisciplinary team approach

American Association of Clinical Endocrinologists (AACE) 2021: Updated guidance incorporating newer evidence on recombinant PTH therapy.

British Association of Endocrine and Thyroid Surgeons (BAETS): Protocols for prevention and early detection of post-thyroidectomy hypoparathyroidism:

• Routine calcium monitoring 4-6 hours post-thyroidectomy
• PTH measurement at conclusion of surgery
• Prophylactic calcium and vitamin D supplementation in high-risk cases

Landmark Clinical Trials

1. REPLACE Trial (2013): Mannstadt M, et al. Lancet Diabetes Endocrinol. [28]

• Design: Randomized, double-blind, placebo-controlled trial of rhPTH(1-84)
• Population: Adults with hypoparathyroidism on conventional therapy
• Intervention: rhPTH(1-84) 50-100 mcg SC daily vs. placebo
• Primary Endpoint: Independence from active vitamin D and ≥50% reduction in calcium supplementation while maintaining serum calcium
• Results:
  • 53% of rhPTH group met primary endpoint vs. 2% placebo
  • Reduced urinary calcium excretion
  • Improved quality of life scores
  • Well tolerated; mild hypercalcemia most common adverse event
• Impact: Led to FDA approval of Natpar (rhPTH 1-84) in 2015

2. PARADOX Trial (2018): Sikjaer T, et al. J Bone Miner Res. [31]

• Design: Crossover RCT comparing rhPTH(1-84) vs. placebo on bone microarchitecture
• Findings:
  • Improved trabecular bone volume and microarchitecture with PTH
  • Maintained bone density
  • Suggests potential bone quality benefits beyond calcium control

3. Long-Term Safety Studies:

• Natpar withdrawn temporarily from EU market in 2019 due to cartridge manufacturing issues, reintroduced in limited form
• Long-term data (5-10 years) emerging on safety and sustained efficacy
• No osteosarcoma cases in human use (rat model black box warning)

Pathophysiology Landmark Studies

4. Rubin MR, et al. (2010) - Bone Microarchitecture in Hypoparathyroidism: J Clin Endocrinol Metab. [20]

• Demonstrated that despite high areal BMD, chronic hypoparathyroidism associated with abnormal trabecular and cortical microarchitecture
• Used high-resolution peripheral quantitative CT (HR-pQCT)
• Suggested potential increased fracture risk despite "osteoporotic" appearance on DXA

5. Mitchell DM, et al. (2012) - Quality of Life in Hypoparathyroidism: J Clin Endocrinol Metab. [25]

• Comprehensive assessment of QoL in 62 hypoparathyroid patients vs. controls
• Demonstrated significant impairments in physical and mental health domains
• Scores comparable to or worse than other chronic diseases
• Not fully explained by biochemical control
• Highlighted unmet need in conventional therapy

Current Evidence Gaps

Areas Requiring Further Research:

• Optimal calcium targets balancing symptoms vs. renal risk
• Fracture risk assessment tools specific to hypoparathyroidism
• Long-term cardiovascular outcomes
• Mechanisms of persistent symptoms despite biochemical control
• Cost-effectiveness of rhPTH therapy
• Pediatric-specific management strategies
• Genetic screening and counseling approaches

---

11. Patient Education and Layperson Explanation

What is Hypoparathyroidism?

Hypoparathyroidism is a condition where four tiny glands in your neck called the parathyroid glands don't produce enough of a hormone called parathyroid hormone (PTH). This hormone is crucial for controlling the amount of calcium in your blood.

Think of calcium as being essential not just for strong bones, but also for:

• Muscle function (including your heart)
• Nerve signaling (sending messages throughout your body)
• Blood clotting
• Many cellular processes

What Causes It?

Surgery (Most Common): The most common cause is accidental injury to the parathyroid glands during thyroid surgery. The parathyroid glands are located right behind the thyroid gland, and despite surgeons' best efforts, they can sometimes be damaged, have their blood supply cut off, or accidentally removed during thyroid operations.

Autoimmune Disease: Sometimes the body's immune system mistakenly attacks the parathyroid glands, destroying them. This can happen alone or as part of a condition where multiple glands are affected.

Genetic: Some people are born with parathyroid glands that don't work properly due to genetic conditions.

What Are the Symptoms?

When calcium levels drop, you might experience:

Tingling and Numbness:

• Pins and needles around your mouth, lips, and fingertips
• This is often the first symptom people notice

Muscle Cramps and Spasms:

• Painful cramps in your hands and feet
• Your hands might curl up into a characteristic position
• In severe cases, spasms of the throat (which is dangerous)

Neurological Symptoms:

• Anxiety, confusion, or mood changes
• Seizures in severe cases
• Fatigue and "brain fog"
• Difficulty concentrating

Long-Term Effects:

• Cataracts (clouding of the lens of the eye)
• Dental problems (if it started in childhood)
• Calcification of parts of the brain (can cause movement problems)

How is it Diagnosed?

Your doctor will perform blood tests showing:

• Low calcium levels
• High phosphate levels (opposite of what's usually seen)
• Low or absent PTH (the key finding)

Additional tests may include urine tests, heart tracings (ECG), and kidney imaging.

How is it Treated?

Unlike most hormone deficiencies, we don't usually replace the missing hormone (PTH) directly because it's expensive, requires daily injections, and isn't widely available. Instead, treatment focuses on:

Calcium Tablets:

• You'll need to take calcium supplements several times daily with meals
• Typical doses are 1-3 grams of elemental calcium per day
• Different forms available (calcium carbonate is most common)

Active Vitamin D:

• Special forms called alfacalcidol or calcitriol
• These bypass the kidney's need for PTH to activate vitamin D
• Regular vitamin D supplements (like vitamin D3 from the pharmacy) won't work well because your kidneys need PTH to activate them

Why Not Aim for "Normal" Calcium? You might wonder why doctors keep your calcium in the "low-normal" range rather than perfectly normal. Here's why:

Without PTH, your kidneys leak calcium into your urine. If your doctor raises your blood calcium to normal levels, even more calcium spills into your urine, which can cause:

• Kidney stones
• Calcium deposits in your kidneys (nephrocalcinosis)
• Kidney damage over time

So the goal is to keep calcium high enough to prevent symptoms but low enough to protect your kidneys.

Additional Medications:

• Magnesium: Some people need magnesium supplements too
• Thiazide diuretics: Water pills that help your kidneys hold onto calcium

Recombinant PTH Injections: For people who don't do well on conventional treatment, a synthetic PTH hormone (Natpar) is available in some countries. It requires daily injections and is very expensive, so it's reserved for difficult cases.

What About Monitoring?

You'll need regular follow-up including:

• Blood tests every few months to check calcium, phosphate, and kidney function
• Urine tests periodically to check calcium excretion
• Kidney ultrasounds every 1-2 years to check for kidney stones or calcification
• Eye exams annually to screen for cataracts

Living with Hypoparathyroidism

Daily Life:

• Take your medications consistently at the same times each day
• Keep extra calcium tablets with you
• Inform all healthcare providers about your condition
• Wear a medical alert bracelet

When to Seek Help: Go to the emergency room if you experience:

• Severe muscle spasms or your hands curling up
• Difficulty breathing or swallowing
• Seizures
• Severe tingling and numbness

Diet:

• Eat calcium-rich foods (dairy, leafy greens, fortified foods)
• Stay well-hydrated (helps protect kidneys)
• Limit salt (excess sodium increases calcium loss in urine)

Illness: When you're sick, vomiting, or can't take your medications, contact your doctor immediately. Illness can destabilize your calcium levels.

Pregnancy and Family Planning

Women with hypoparathyroidism can have successful pregnancies, but they require:

• Close monitoring throughout pregnancy
• Medication adjustments (calcium needs increase)
• Coordination between endocrinology and obstetrics teams
• Careful monitoring of the baby

Discuss family planning with your endocrinologist early.

Prognosis

With proper treatment, most people with hypoparathyroidism can live normal lifespans. However, many patients report:

• Persistent fatigue despite normal blood tests
• Reduced quality of life compared to before diagnosis
• Ongoing challenges with concentration and "brain fog"

Researchers are working to understand why conventional treatment doesn't completely restore quality of life and whether PTH replacement therapy offers advantages.

Support and Resources

• Endocrine Society patient resources
• Hypoparathyroidism Association (HypoPara)
• National Organization for Rare Disorders (NORD)
• Local patient support groups

---

12. References

Primary Literature

1. Bollerslev J, Rejnmark L, Marcocci C, et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015;173(2):G1-G20. doi:10.1530/EJE-15-0628. PMID: 26160136

2. Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26(10):2317-2337. doi:10.1002/jbmr.483. PMID: 21812031

3. Clarke BL, Brown EM, Collins MT, et al. Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab. 2016;101(6):2284-2299. doi:10.1210/jc.2015-3908. PMID: 26943719

4. Goltzman D, Hendy GN. The calcium-sensing receptor in bone—mechanistic and therapeutic insights. Nat Rev Endocrinol. 2015;11(5):298-307. doi:10.1038/nrendo.2015.13. PMID: 25687881

5. Cusano NE, Rubin MR, Bilezikian JP. Parathyroid hormone therapy for hypoparathyroidism. Best Pract Res Clin Endocrinol Metab. 2015;29(1):47-55. doi:10.1016/j.beem.2014.09.001. PMID: 25617172

6. Witteveen JE, van Thiel S, Romijn JA, Hamdy NA. Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol. 2013;168(3):R45-R53. doi:10.1530/EJE-12-0528. PMID: 23152439

7. Rude RK. Magnesium deficiency and diabetes mellitus: causes and effects. Postgrad Med. 1992;92(5):217-224. doi:10.1080/00325481.1992.11701433. PMID: 1518760

8. Schaaf M, Payne CA. Effect of diphenylhydantoin and phenobarbital on overt and latent tetany. N Engl J Med. 1966;274(22):1228-1233. PMID: 5934954

9. Napolitano C, Bloise R, Monteforte N, Priori SG. Sudden cardiac death and genetic ion channelopathies: long QT, Brugada, short QT, catecholaminergic polymorphic ventricular tachycardia, and idiopathic ventricular fibrillation. Circulation. 2012;125(16):2027-2034. doi:10.1161/CIRCULATIONAHA.111.055947. PMID: 22529064

10. Powers J, Joy K, Ruscio A, Lagast H. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013;28(12):2570-2576. doi:10.1002/jbmr.2004. PMID: 23737456

11. Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg. 2014;101(4):307-320. doi:10.1002/bjs.9384. PMID: 24402815

12. Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab. 2016;101(6):2300-2312. doi:10.1210/jc.2015-3909. PMID: 26943721

13. Orloff LA, Wiseman SM, Bernet VJ, et al. American Thyroid Association statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults. Thyroid. 2018;28(7):830-841. doi:10.1089/thy.2017.0309. PMID: 29665772

14. Lorente-Poch L, Sancho JJ, Ruiz S, Sitges-Serra A. Importance of in situ preservation of parathyroid glands during total thyroidectomy. Br J Surg. 2015;102(4):359-367. doi:10.1002/bjs.9676. PMID: 25605481

15. Husebye ES, Anderson MS, Kämpe O. Autoimmune polyendocrine syndromes. N Engl J Med. 2018;378(12):1132-1141. doi:10.1056/NEJMra1713301. PMID: 29562162

16. Constantine GM, Lionakis MS. Lessons from primary immunodeficiencies: autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Immunol Rev. 2019;287(1):103-120. doi:10.1111/imr.12714. PMID: 30565246

17. McDonald-McGinn DM, Sullivan KE, Marino B, et al. 22q11.2 deletion syndrome. Nat Rev Dis Primers. 2015;1:15071. doi:10.1038/nrdp.2015.71. PMID: 27189754

18. Habeb AM, Al-Magamsi MS, Eid IM, et al. Incidence, genetics, and clinical phenotype of permanent neonatal diabetes mellitus in Northwest Saudi Arabia. Pediatr Diabetes. 2012;13(6):499-505. doi:10.1111/j.1399-5448.2011.00828.x. PMID: 22060631

19. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev. 2016;96(1):365-408. doi:10.1152/physrev.00014.2015. PMID: 26681795

20. Rubin MR, Dempster DW, Zhou H, et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008;23(12):2018-2024. doi:10.1359/jbmr.080803. PMID: 18684087

21. Rejnmark L, Underbjerg L, Sikjaer T. Hypoparathyroidism: replacement therapy with parathyroid hormone. Endocrinol Metab Clin North Am. 2018;47(4):865-877. doi:10.1016/j.ecl.2018.07.011. PMID: 30390812

22. Thakker RV. Genetic developments in hypoparathyroidism. Lancet. 2001;357(9261):974-976. doi:10.1016/S0140-6736(00)04240-6. PMID: 11293641

23. Saleem S, Aslam HM, Anwar M, et al. Fahr's syndrome: literature review of current evidence. Orphanet J Rare Dis. 2013;8:156. doi:10.1186/1750-1172-8-156. PMID: 24098963

24. Levine MA. An update on the clinical and molecular characteristics of pseudohypoparathyroidism. Curr Opin Endocrinol Diabetes Obes. 2012;19(6):443-451. doi:10.1097/MED.0b013e32835a255c. PMID: 23076042

25. Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002;146(2):215-222. doi:10.1530/eje.0.1460215. PMID: 11834431

26. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013;28(11):2277-2285. doi:10.1002/jbmr.1979. PMID: 23661265

27. Porter RH, Cox BG, Heaney D, Hostetter TH, Stinebaugh BJ, Suki WN. Treatment of hypoparathyroid patients with chlorthalidone. N Engl J Med. 1978;298(10):577-581. doi:10.1056/NEJM197803092981101. PMID: 625261

28. Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013;1(4):275-283. doi:10.1016/S2213-8587(13)70106-2. PMID: 24622414

29. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Postsurgical hypoparathyroidism—risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. 2014;29(11):2504-2510. doi:10.1002/jbmr.2273. PMID: 24825359

30. Almquist M, Hallgrimsson P, Nordenström E, Bergenfelz A. Prediction of permanent hypoparathyroidism after total thyroidectomy. World J Surg. 2014;38(10):2613-2620. doi:10.1007/s00268-014-2622-z. PMID: 24867473

31. Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011;26(10):2358-2370. doi:10.1002/jbmr.470. PMID: 21698667

---

13. Examination Focus

High-Yield MRCP/FRACP Questions

Question 1: Biochemical Diagnosis

A 45-year-old woman undergoes total thyroidectomy for papillary thyroid carcinoma. On postoperative day 2, she develops perioral tingling and carpopedal spasm. Laboratory results:

• Adjusted calcium: 1.85 mmol/L (2.2-2.6)
• Phosphate: 1.8 mmol/L (0.8-1.4)
• PTH: 0.8 pmol/L (1.5-7.0)
• Magnesium: 0.75 mmol/L (0.7-1.0)

Which diagnosis is most likely? A) Vitamin D deficiency B) Hypoparathyroidism C) Pseudohypoparathyroidism D) Hungry bone syndrome E) Hypomagnesemia

Answer: B) Hypoparathyroidism

Explanation: The biochemical triad of hypocalcaemia, hyperphosphataemia, and low PTH in the setting of recent thyroid surgery is pathognomonic for post-surgical hypoparathyroidism. Magnesium is normal, excluding functional hypoparathyroidism.

---

Question 2: Treatment Selection

A patient with chronic hypoparathyroidism is on calcium carbonate 1.5 g TDS and cholecalciferol 1000 IU daily. Despite good adherence, calcium remains 1.95 mmol/L with symptomatic paresthesias. What is the most appropriate next step?

A) Increase cholecalciferol to 5000 IU daily B) Switch to calcium citrate C) Add alfacalcidol D) Start thiazide diuretic E) Refer for recombinant PTH therapy

Answer: C) Add alfacalcidol

Explanation: Cholecalciferol requires PTH-dependent renal 1α-hydroxylation to become active. In hypoparathyroidism, this step is impaired. Active vitamin D analogs (alfacalcidol or calcitriol) bypass this requirement and are essential for management.

---

Question 3: Target Setting

Why is the target serum calcium in chronic hypoparathyroidism maintained in the low-normal range (2.0-2.2 mmol/L) rather than mid-normal?

A) To prevent tetany B) To reduce risk of hypercalciuria and nephrocalcinosis C) To avoid QT prolongation D) To prevent basal ganglia calcification E) To reduce PTH secretion

Answer: B) To reduce risk of hypercalciuria and nephrocalcinosis

Explanation: Without PTH, the kidney cannot reabsorb calcium efficiently. Raising serum calcium to mid-normal increases filtered calcium load, exacerbating urinary calcium loss and increasing nephrocalcinosis risk.

---

Question 4: Emergency Management

A 38-year-old woman with known hypoparathyroidism presents to the emergency department with generalized tonic-clonic seizure. She is post-ictal. Ionized calcium is 0.85 mmol/L (1.1-1.3). ECG shows QTc 520 ms. What is the most appropriate immediate management?

A) Oral calcium carbonate 2 g stat B) IV calcium gluconate 10 ml of 10% solution over 10 minutes C) IM calcium gluconate D) Oral alfacalcidol 2 mcg stat E) IV magnesium sulfate

Answer: B) IV calcium gluconate 10 ml of 10% solution over 10 minutes

Explanation: Acute symptomatic hypocalcaemia (seizure, prolonged QTc) requires immediate IV calcium replacement. Oral therapy is inadequate in emergencies. Magnesium is not indicated (not mentioned as low).

---

Question 5: Differential Diagnosis

Which biochemical pattern distinguishes hypoparathyroidism from vitamin D deficiency?

Answer:

Key Discriminator: PTH is low in hypoparathyroidism but appropriately elevated in vitamin D deficiency. Phosphate is high (loss of PTH phosphaturic effect) versus low (PTH-driven phosphate wasting).

---

Viva Voce Scenarios

Scenario 1: Post-Thyroidectomy Hypocalcaemia

Examiner: "You are the medical registrar. A 52-year-old woman is 6 hours post-total thyroidectomy. The nursing staff reports she has tingling in her fingers. What would you do?"

Model Answer Structure:

1. Assess urgency: Is she having tetany, laryngospasm, or seizures? (Emergency)
2. Immediate investigations: Ionized calcium, PTH, magnesium, ECG
3. Examination: Trousseau's sign, Chvostek's sign
4. Biochemistry interpretation:
   • Low calcium + low PTH = hypoparathyroidism
   • Check if transient (gland stunning) vs. permanent (requires 6 months)
5. Management:
   • If symptomatic/severe: IV calcium gluconate
   • If mild: Oral calcium carbonate + alfacalcidol
   • Correct magnesium if low
6. Follow-up: Daily calcium monitoring; reassess at 6 months for permanence

Examiner Follow-Up: "Why alfacalcidol and not normal vitamin D?"

Answer: Alfacalcidol is 1α-hydroxylated vitamin D. It bypasses the kidney's requirement for PTH to activate vitamin D. Cholecalciferol needs renal 1α-hydroxylase (PTH-dependent) to become active 1,25(OH)₂D, which is impaired in hypoparathyroidism.

---

Scenario 2: Fahr's Syndrome

Examiner: "This 60-year-old man with long-standing hypoparathyroidism presents with progressive bradykinesia and rigidity. His CT brain is shown (basal ganglia calcification). What is the diagnosis and management?"

Model Answer:

• Diagnosis: Fahr's syndrome (basal ganglia calcification secondary to chronic hypoparathyroidism)
• Pathophysiology: Chronic hypocalcaemia and hyperphosphataemia promote calcium-phosphate deposition in basal ganglia
• Clinical features: Extrapyramidal signs (parkinsonism, dystonia, chorea), cognitive impairment, psychiatric symptoms
• Management:
  • "Optimize calcium and phosphate: May halt progression but won't reverse established calcification"
  • "Symptomatic treatment: Dopaminergic agents (levodopa) for parkinsonism, though response variable"
  • "Prognosis: Established calcification is irreversible"
  • "Prevention: Early diagnosis and optimal control of hypoparathyroidism"

---

Scenario 3: Pseudohypoparathyroidism

Examiner: "How do you distinguish between hypoparathyroidism and pseudohypoparathyroidism?"

Model Answer:

Key Point: PTH level is the critical discriminator—low in true hypoparathyroidism, high in pseudohypoparathyroidism.

---

Scenario 4: Pregnancy in Hypoparathyroidism

Examiner: "A 28-year-old woman with post-surgical hypoparathyroidism is planning pregnancy. What counseling would you provide?"

Model Answer:

1. Feasibility: Successful pregnancy is achievable with meticulous management
2. Physiological changes:
   • Increased calcium demands (fetal skeletal development)
   • Placental calcitriol production may reduce alfacalcidol requirements
   • Maternal hypocalcaemia can cause fetal hyperparathyroidism
3. Management adjustments:
   • Preconception optimization of calcium
   • Monthly calcium monitoring during pregnancy
   • Likely need to increase calcium supplementation in 2nd-3rd trimester
   • May need to reduce alfacalcidol dose (placental production)
   • Target ionized calcium low-normal range
4. Multidisciplinary care: Coordinate with maternal-fetal medicine, endocrinology
5. Neonatal: Monitor infant calcium postpartum
6. Breastfeeding: Can continue; calcium demands persist; continue supplementation

---

Clinical Examination Pearls

Trousseau's Sign Technique:

1. Inflate BP cuff on arm to 20 mmHg above systolic pressure
2. Maintain inflation for 3 minutes
3. Observe for carpopedal spasm:
   • Wrist flexion
   • MCP flexion, IP extension
   • Thumb adduction (main d'accoucheur)
4. Sensitivity: 94% in hypocalcaemia; Specificity: 99%

Chvostek's Sign Technique:

1. Tap facial nerve anterior to ear
2. Observe for ipsilateral facial twitching
3. Less specific: 10-30% false positive rate in normocalcaemic individuals

ECG Interpretation:

• Measure QTc interval (Bazett's formula)
• Look for ST segment prolongation ("plateau" appearance)
• Distinguish from other long QT causes (predominantly T-wave abnormalities)

Physical Examination in Chronic Cases:

• Skin: Dry, coarse; eczema
• Nails: Brittle
• Teeth: Enamel hypoplasia (if childhood onset)
• Eyes: Posterior subcapsular cataracts (slit-lamp)
• Neurological: Extrapyramidal signs if basal ganglia calcification

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and be made in consultation with appropriate specialists. Treatment guidelines evolve; always consult current evidence and local protocols.